NantKwest, Inc. (NK)
| Market Cap | 3.54B |
| Revenue (ttm) | 99,000 |
| Net Income (ttm) | -75.89M |
| Shares Out | 108.25M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $32.51 |
| Previous Close | $34.18 |
| Change ($) | -1.67 |
| Change (%) | -4.89% |
| Day's Open | 33.95 |
| Day's Range | 30.80 - 35.91 |
| Day's Volume | 1,405,933 |
| 52-Week Range | 2.52 - 45.42 |
The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Inc's (NASDAQ: NK) merger partner, ImmunityBio Inc, to include sublingual boosts...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics comp...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of NantKw...
BERWYN, Pa., Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerni...
NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty ag...
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurod...
NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBio's imp...
Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday. What Happened: ...
EL SEGUNDO & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, Inc., a privately-held immun...
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executiv...
"Natural killer" (or NK) cancer therapies are hot right now. Here are two stocks that are early leaders in the field -- one is a buy, and the other one is not.
PHILADELPHIA, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.
WILMINGTON, Del., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potent...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of NantKwest, Inc. (NASDAQ:NK) and ImmunityBio is fair to NantKwest sharehol...
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
WILMINGTON, Del., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ GS: NK) regarding possible breaches of fiduc...
NantKwest's Patrick Soon-Shiong on reverse merger with ImmunityBio
NantKwest announces a reverse merger with a frequent collaborator ImmunityBio in a stock-for-stock deal. Patrick Soon-Shiong, NantKwest executive chairman and NantWorks chairman and CEO, joins...
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NantKwest, Inc. ("NantKwest" ...
A merger agreement with a fellow immunotherapy company is exciting investors today.
CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based th...
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annua...
CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based th...
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven ope...
NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300.
CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based th...
EL SEGUNDO, Calif. & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held imm...
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman an...
SAN DIEGO--(BUSINESS WIRE)--Brink Biologics, Inc. (“Brink”), a NantKwest, Inc.
EL SEGUNDO, Calif. & CULVER CITY, Calif.
LOS ANGELES, and EL SEGUNDO, Calif., Aug. 10, 2020 /PRNewswire/ -- CBR® by Generate Life Sciences, the world's largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-st...
NantKwest (NK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
My COVID-19 Vaccine Report Card
NantKwest: The Market And The Government Are Missing Out On This Blockbuster
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced und...
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offer...
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject ...
Investors are excited about the biotech's COVID-19 vaccine targeting a different part of the novel coronavirus.
Nantkwest Inc (NASDAQ: NK) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options.
Shares of small-cap immunotherapy company Nantkwest Inc (NASDAQ: NK), a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, were adding to Monday's gains in...
Investors need to pay close attention to NantKwest (NK) stock based on the movements in the options market lately.
Shares soar after the clinical-stage biotech releases exciting news.
NantKwest: The Market Finally Recognizes The Opportunity
NantKwest has recently reported positive results and progress in its NK cell pipeline programs, but the shares have continued to sell off.
NantKwest was a highly anticipated IPO that only took a couple of years to be "busted" Although the stock might be busted, the company is still making headway.
As of late, it has definitely been a great time to be an investor in NantKwest.
About NK
NantKwest, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cance... [Read more...]
| Industry Biotechnology | IPO Date Jul 28, 2015 |
| CEO Patrick Soon-Shiong | Employees 160 |
| Stock Exchange NASDAQ | Ticker Symbol NK |
Financial Performance
In 2019, NantKwest's revenue was $43,000, a decrease of -8.51% compared to the previous year's $47,000. Losses were -$65.79 million, -31.63% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for NantKwest stock is "Buy" and the 12-month stock price forecast is 18.00.